Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C36H49Cl2N6O6S |
Molecular Weight | 764.782 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 1 |
SHOW SMILES / InChI
SMILES
CC1=NC2=C(C=CC=C2OCC3=C(Cl)C=CC(=C3Cl)S(=O)(=O)NC4(CCOCC4)C(=O)N5CCN(CC5)C(=O)[C@@H](N)CCC[N+](C)(C)C)C(C)=C1
InChI
InChIKey=FQVSDHOWSLEEKJ-LJAQVGFWSA-N
InChI=1S/C36H49Cl2N6O6S/c1-24-22-25(2)40-33-26(24)8-6-10-30(33)50-23-27-28(37)11-12-31(32(27)38)51(47,48)41-36(13-20-49-21-14-36)35(46)43-17-15-42(16-18-43)34(45)29(39)9-7-19-44(3,4)5/h6,8,10-12,22,29,41H,7,9,13-21,23,39H2,1-5H3/q+1/t29-/m0/s1
Fasitibant (MEN-16132) is a non-peptide sulfonamide-containing bradykinin hB2 receptor antagonist. It inhibits pro-inflammatory response in vitro and alleviates inflammatory hyperalgesia in rodent models of osteoarthritis. Menarini Group was developing fasitibant for the treatment of osteoarthritis. Fasitibant development has been discontinued.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02205814
Unknown
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22638761
Incubation of synoviocytes with BK induced a sustained production of PGE(2) and transient COX-2 gene expression that were prevented by pretreatment with fasitibant (1 μM, 30 min preincubation).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB15646
Created by
admin on Fri Dec 15 15:47:32 GMT 2023 , Edited by admin on Fri Dec 15 15:47:32 GMT 2023
|
PRIMARY | |||
|
DTXSID30236032
Created by
admin on Fri Dec 15 15:47:32 GMT 2023 , Edited by admin on Fri Dec 15 15:47:32 GMT 2023
|
PRIMARY | |||
|
0WL827Z7AE
Created by
admin on Fri Dec 15 15:47:32 GMT 2023 , Edited by admin on Fri Dec 15 15:47:32 GMT 2023
|
PRIMARY | |||
|
100000175070
Created by
admin on Fri Dec 15 15:47:32 GMT 2023 , Edited by admin on Fri Dec 15 15:47:32 GMT 2023
|
PRIMARY | |||
|
869939-83-3
Created by
admin on Fri Dec 15 15:47:32 GMT 2023 , Edited by admin on Fri Dec 15 15:47:32 GMT 2023
|
PRIMARY | |||
|
11498853
Created by
admin on Fri Dec 15 15:47:32 GMT 2023 , Edited by admin on Fri Dec 15 15:47:32 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)